Compare Amgen, Inc. (AMGN) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Synchrony Financial — how do they compare? Amgen, Inc. trades at $359.22 (market cap $196.12B), while Synchrony Financial trades at $73.04 (market cap $24.37B). The key difference: Amgen, Inc. is far larger — about 8× Synchrony Financial's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | SYF | |
|---|---|---|
Market Cap | $196.12B | $24.37B |
Sector | Health | Financials |
52-Week High | $388.16 | $88.47 |
52-Week Low | $271.18 | $63.78 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Synchrony Financial (SYF) trades at $72.44, up 1.22% with strong fundamental metrics including a low P/E of 7.5 and robust ROE of 22.98%. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 results expected July 21. Technical indicators show bearish momentum despite neutral oscillators, with key support at $69 and resistance at $73. Recent corporate developments include executive leadership changes and expansion of CareCredit partnerships.
SYF presents a compelling value opportunity with attractive valuation multiples and consistent earnings performance. The stock offers 19% upside to consensus price target of $86, supported by strong analyst sentiment (62.5% buy ratings). Key risks include economic sensitivity to consumer credit and inflationary pressures. The upcoming Q2 earnings report will be crucial for confirming the company's growth trajectory amid current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
